上市捷报丨沙利文祝贺江苏康为世纪生物科技股份有限公司成功登陆科创板(688426.SH)

Jiangsu Kangwe Century Biotechnology Co., Ltd. (Stock Code:688426.SH) on2022year10month25Rising Star successfully accessed the Sci-tech Innovation Board. Kangwei Century, based on its independent R&D of core technologies at the molecular detection level, has over a decade of experience in enzyme raw materials, nucleic acid preservation, and sample pretreatment. It is one of the few biotech companies in China that have achieved a complete business layout for the core molecular detection links. Frost & SullivanFrost & SullivanFrost & Sullivan, hereinafter referred to as 'Frost & Sullivan', hereby warmly congratulates the company on its successful listing.

Jiangsu Kangwe Century Biotechnology Co., Ltd. (hereinafter referred to as 'Kangwe Century') was established in2022year10month25The company was successfully listed on the stock market, with the number of shares issued being2,329.027810,000 shares, issue price per share48.98yuan.

Based on the company's independent R & D of underlying molecular detection technologies, it has established a product line covering the core links of the molecular detection industry. Its products are mainly supplied to participants in the upstream and downstream of the molecular detection industry, empowering customers with R & D, production, and services related to molecular detection.
Based on the technical advantages of each core link in molecular detection, the company has expanded its business into the fields of screening and diagnosis of digestive tract diseases and respiratory infectious diseases. It has developed a number of innovative products and services, realizing molecular detection “core enzyme raw materials+kit+Integrated layout of detection services ”
The company has a vast and complete product system, with up to700Yu Zhong, holding nearly80Registration and filing of medical devices both within and outside the province;
The company has established a complete intellectual property system and holds dozens of patents;
The company has an experienced management team with a deep understanding of the molecular testing industry and market.

Frost & Sullivan has long been monitoring the global and Chinese biopharmaceutical industries, publishing a large number of research reports that are widely cited in the prospectuses of leading science and technology innovation board listed companies in the industry, helping clients accelerate their growth.

Industry position

2020After the outbreak of the COVID-19 pandemic in 2020, the demand for virus sample preservation reagents increased rapidly, making it the main product type among pathogen preservation reagents.

The market for virus preservation reagents in China is relatively fragmented.2020In the year, Kangweishiji ranked third among domestic brands, accounting for4%.

At the same time, the demand for nucleic acid extraction due to COVID-19 nucleic acid testing has also increased significantly.2020Niankang ranks fourth among domestic brands in terms of market share3.9%.

Molecular Detection Market Overview

In recent years, with the aging population, increasing health awareness, and advancements in emerging technologies, the market size of molecular testing has been steadily growing. The domestic molecular testing industry has also developed rapidly.2020In [year], the market scale of molecular testing in China reached361.7Yuan billion; In the next five years, the improvement of China's hierarchical medical system, technological innovation, and support from relevant policies will continue to drive the development of the molecular testing industry. It is expected that2025In [year], the market scale of molecular testing in China will reach480.7100 million yuan.

Overview of the Molecular Detection Enzyme Raw Material Market

The raw material enzyme industry for molecular detection is at the upstream of the molecular detection industry's industrial chain. The broad development prospects of the molecular detection reagent market will feed back into the growth of the molecular detection enzyme raw material market.2020In the face of huge demand for nucleic acid testing in [year], there is an urgent need to meet rigid demands from the market for molecular diagnostic reagents. The domestic market scale of raw material enzymes for molecular detection has changed from2016year14.0RMB billion growth to2020of32.1yuan, expected to reach2025In [year], the market scale of domestic molecular detection raw material enzymes will reach52.1100 million yuan.

Market Scale and Forecast of China's Molecular Detection Enzyme Raw Materials

2016Year to2025Year (estimated)

Data source: Analysis by Frost & Sullivan

Nucleic Acid Preservation Market Overview

In recent years, with the development of China's molecular testing industry, the popularization of cancer early screening and home testing, and breakthroughs in sample preservation technology, the market scale of nucleic acid sample preservation reagents in China has been steadily growing.2020The COVID-19 pandemic that broke out in 2020 accelerated the market demand for molecular testing in China, leading to an increase in the market for nucleic acid sample preservation reagents.2016Year-end2020In [year], the market for nucleic acid sample preservation reagents in China was from5.5RMB billion growth to24.7Yuan, with a compound annual growth rate for the period of45.5%In the next five years, the molecular testing industry will continue to maintain a relatively fast development pace, up to2025In [X] year, the market scale of nucleic acid sample preservation reagents in China will reach43.9yuan, with an annual growth rate for the forecast period of12.2%.

Market Scale and Forecast of Nucleic Acid Sample Preservation in China

2016Year-end2025Year (estimated)

Data source: Analysis by Frost & Sullivan

Market Overview of Nucleic Acid Extraction and Purification

The main driving force for the growth of the domestic nucleic acid extraction market comes from the gradual promotion of tumor early screening.2020The outbreak of the COVID-19 pandemic in that year also led to a surge in the market size for nucleic acid extraction and purification.2016Year to2020The domestic nucleic acid extraction and purification reagent market in3.4RMB billion growth to16.8Yuan, with a compound annual growth rate for the period of49.3%In addition, with the technological development of local Chinese enterprises, their lower market prices and communication costs will drive an overall increase in market size, up to2025In [year], the market scale of nucleic acid extraction and purification kits in China will reach25.7yuan, with an annual growth rate for the forecast period of10.1%.

Market Scale and Forecast of Nucleic Acid Extraction and Purification Kits in China

2016Year-end2025Year (estimated)

Data source: Analysis by Frost & Sullivan

Market Overview of Molecular Detection for Digestive System Diseases

The company's molecular detection product development in the field of digestive tract disease screening and diagnosis mainly focuses on Helicobacter pylori and colorectal tumor screening. The market situation in these areas is as follows:

（1) Overview of Helicobacter pylori Screening Market

Helicobacter pylori screening is currently the most commonly used method for gastric cancer screening. According to Frost & Sullivan statistics,2020The penetration rate of Helicobacter pylori screening among the recommended population for gastric cancer screening has reached11.3%The market potential is about120Yuan. In the future, with the continuous improvement of public health management awareness, the penetration rate of Helicobacter pylori screening is expected to continue to rise, and the market scale for Helicobacter pylori screening will continue to grow.

（2Overview of the colorectal tumor screening market

The screening for colorectal cancer in China is still in its early stages of development. However, in recent years, due to increased government support, improved public awareness, and updates to the colorectal cancer screening guidelines that recommend regular screenings, the penetration rate among those who are advised to undergo cancer screening has significantly increased.2016year14.1%Grew to2020year17.5%, expected to be launched in2025Annual achievement26.4%The colorectal cancer screening market in China is composed of2016year26RMB 100 million increased to2020year33yuan, with a compound annual growth rate of6.4%, and it is expected to grow at a compound annual rate19.9%Further increase to2025year76100 million yuan.

Market scale and forecast of colorectal cancer screening in China

2016Year-end2025Year (estimated)

Note: The colorectal cancer screening market is used for cancer screeningFOBT/FITProducts and genetic testing products (for exampleFIT-DNACalculated based on the ex-factory price of (test)

Data source: Analysis by Frost & Sullivan

Overview of the Molecular Detection Market for Respiratory Infectious Diseases

The outbreak of the COVID-19 pandemic has heightened public attention to molecular testing for respiratory infectious pathogens, significantly boosting market potential. 'National Influenza Prevention and Control Work Plan (2020The (2021 Edition) states that strict pre-triage and separate diagnosis and treatment of respiratory infectious diseases are necessary, promoting the combined detection of multiple pathogens in respiratory infectious diseases, and supporting the simultaneous testing for various pathogens such as the novel coronavirus and influenza virus. The 'Diagnosis and Treatment Protocol for Pneumonia Caused by Novel Coronavirus Infection (Trial Seventh Edition)' also requires the differentiation between mild manifestations of novel coronavirus infection and upper respiratory tract infections caused by other viruses, mainly including influenza virus, adenovirus, respiratory syncytial virus, etc., which require rapid antigen testing and multiplePCRNucleic acid testing and other methods are used to detect common respiratory pathogens.

Compared with immunological products targeting respiratory pathogens, molecular testing has superior sensitivity and specificity. Therefore, it has been widely implemented by governments around the world since the early stages of the COVID-19 pandemic as the gold standard for diagnosing COVID-19 infections. According to Frost & Sullivan statistics, domestically2020The market scale of COVID-19 molecular testing reached198yuan. In molecular detection technologies for respiratory system diseases, point-of-care testingPOCTTechnologies for combined detection of multiple pathogens are a development trend. In the future, China may face long-term pressure from imported COVID-19 cases, making the differential diagnosis between influenza and COVID-19 increasingly important. The launch of combined detection products will further meet the testing needs under the epidemic context.

Frost & Sullivan integrates the globe.61years of consulting experience,24Frost & Sullivan has been dedicated to serving the booming Chinese market for years, demonstrating a global perspective in helping clients accelerate their business growth and achieve industry-leading benchmarks in terms of growth, innovation, and leadership. The health industry is one of the core areas of focus for Frost & Sullivan. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare service, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listing cases include: GenSight Biotech9877.HK), HealthyuanJCARE.SW), Leopu MedicalLEPU.SW), DINGDANG HEALTH9886.HK), Baidu Map Suggest (2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（PRE.NASDAQ), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leepu Biotech2157.HK), Clear Medical (1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhui Kaiman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Med66 (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital (2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature Medicine (UPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Medical (9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novo Nordisk China (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), ViaBio1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Biopharmaceuticals2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. In terms of the number of submissions, Frost & Sullivan's healthcare team in Hong Kong is involved inIPO listingMaintain an absolute leading position,2018till2021Year after year, it has always ranked first in market share.

since2019year7Since the first batch of companies on the Sci-tech Innovation Board were listed, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board-listed companies in the industry, including: Onshore Protein (688137.SH), Novartis HealthCare (688428.SH), OPUMAI BIOLOGY688293.SH), minimally invasive electrophysiology688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui YAKANG688046.SH), Haichuang Pharmaceutical688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Pharmaceutical Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and other institutions are considered one of the most powerful, professional, and influential industry research organizations in the sector. We aim to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.